DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for kids with DIPG: major trial tests promising drug
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The go…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
New hope for kids with rare brain cancer: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called lorlatinib in children (ages 1-21) with a newly diagnosed, aggressive brain tumor that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor and to check its safety when given alone or wit…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: EARLY_PHASE1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 20, 2026 11:55 UTC